Introduction
Component | |
---|---|
1 | Identification of groups at risk of having LTBI or an increased risk of progressing to active TB. These target groups should be prioritized for LTBI screening and treatment |
2 | Definition of diagnostic approach for LTBI detection, including both the selection of diagnostic test(s) and the diagnostic algorithm most appropriate for each target group |
3 | Provision of LTBI treatment using treatment regimens that are effective and promote adherence and completion by different target groups |
4 | Implementation of patient-centred strategies for service delivery |
5 | Effective health education and communication with target groups and health care providers |
6 | Programme monitoring and evaluation |
Cohorts which should be programmatically screened and treated in all EU/EEA countries | Cohorts where programmatic screening and treatment is dependent on the country specific LTBI epidemiology and resources available |
---|---|
Immunosuppressed persons (such as patients on anti-TNF alpha treatment), | People who are homeless |
People living with HIV (regardless of CD4 cell count or HIV antiretroviral therapy status) | People who use drugs |
Patients preparing for transplantation | Prison inmates |
Patients with end-stage renal diseases and/or preparing for dialysis | Immigrants from countries with a high TB incidence |
Patients with silicosis; people with pulmonary fibrotic lesions | Health care workers |
Contacts of infectious TB cases (based on a risk assessment of their exposure) |
Methods
Results
Search results
Characteristics of included studies
Study | Study design* | Setting | Cohort (cohort size) |
---|---|---|---|
Gnanasekaran et al. [17] | Retrospective | Secondary centre | Pre-biologic screening in patients with IA (n = 39) |
O’Flynn et al. [18] | Retrospective | Tertiary centre | Pre-biologic screening in patients with IA (n = 70) |
Awan et al. [19] | Prospective | Secondary centre | Pre-biologic screening in patients with IA (n = 25) |
O’Flynn et al. [20] | Prospective | Tertiary centre | Pre-biologic screening in patients with IA (n = 109) |
Hurley et al. [21] | Retrospective | Tertiary centre | Pre-organ transplantation screening (n = 101) |
Safwat et al. [22] | Retrospective | Secondary centre | Pre-biologic screening (43% of cohort) (n = 78) |
Haroon et al. [23] | Prospective | Tertiary centre | Pre-biologic screening in patients with IA (n = 132) |
O’Flynn [24] | Unclear | Tertiary centre | Pre-biologic screening in patients with IA (n = 188) |
Martin et al. [25] | Prospective | Tertiary centre | Pre-biologic screening in patients with IA (n = 150) |
Jordan et al. [26] | Retrospective | Tertiary centre | Pre-biologic screening in patients with IA (n = 63) |
Kelly et al. [27] | Retrospective | Tertiary centre | Pre-biologic screening in patients with psoriasis (n = 101) |
Ní Cheallaigh et al. [28] | Prospective | Tertiary centre | People living with HIV (n = 256) |
Ali et al. [29] | Retrospective | Tertiary centre | PLWHIV (n = 331), Occupational screening of new entrant health care workers (n = 2410) |
Higgins et al. [30] | Retrospective | PHD | TB outbreak (6 cases) in the community (n = 268) |
Glynn et al. [31] | Prospective | PHD | Contact tracing of 39 sporadic TB cases (n = 701) |
O’Donovan et al. [32] | Prospective | PHD | TB outbreak (6 cases) in university students (n = 71) |
O’Meara et al. [33] | Retrospective | PHD | TB outbreak (3 cases) in a primary school (n = 307) |
O’Sullivan et al. [34] | Retrospective | PHD | TB outbreak (13 cases) in a secondary school (n = 1200) |
Bambury et al. [35] | Retrospective | PHD | Contact tracing of 118 sporadic TB cases (n = 1082) |
Gaensbaeur et al. [36] | Prospective | PHD | TB outbreak in two creches (n = 268) |
Hennessy [37] | Retrospective | PHD | Children tuberculin skin tested before BCG (1854) |
Tam et al. [38] | Retrospective | Tertiary centre | TB-related referrals to a specialist paediatric clinic (n = 13) |
Millar et al. [39] | Retrospective | PHD | Asylum seekers attending communicable disease screening in Cork and Kerry (n = 4780) |
Doyle et al. [40] | Retrospective | PHD | Asylum seekers undergoing communicable disease screening 1998–2003 (n = 236) |
Smyth et al. [41] | Retrospective | Unknown | Health care workers with significant exposure to infectious TB (n = 41) |
Kelly et al. [42] | Retrospective | Tertiary centre | Occupational screening of overseas health care workers (n = 505) |
Power et al. [43] | Retrospective | Tertiary centre | Overseas nursing recruits from India (n = 54) |
Arya et al. [44] | Retrospective | Tertiary centre | Health care workers with a positive TST referred to the TB clinic (n = 243) |
Study | Screening test(s) reported | Outcome(s) reported | |||||
---|---|---|---|---|---|---|---|
Proportion screened | Proportion screened positive | Proportion offered prophylaxis | Proportion accepting prophylaxis | Proportion completing prophylaxis | Cost of screening/treatment | ||
Studies evaluating latent TB infection screening in immunosuppressed patients | |||||||
Gnanasekaran et al. [17] | IGRA, CXR | Yes | Yes | Yes | Yes | Yes | No |
O’Flynn et al. [18] | Unclear | No | Yes | No | No | No | No |
Awan et al. [19] | IGRA, TST | No | Yes | Yes | Yes | Yes | No |
O’Flynn et al. [20] | IGRA | No | Yes | Yes | Yes | No | No |
Hurley et al. [21] | IGRA, TST | No | Yes | No | No | No | No |
Safwat et al. [22] | IGRA, TST, CXR | No | Yes | No | No | No | No |
Haroon et al. [23] | TST, CXR | No | Yes | Yes | Yes | Yes | No |
O’Flynn 2012 [24] | IGRA, TST, CXR | No | Yes | Yes | Yes | No | No |
Martin et al. [25] | IGRA, CXR | No | Yes | No | No | No | No |
Jordan et al. [26] | IGRA, TST, CXR | No | Yes | Yes | Yes | Yes | Yes |
Kelly et al. [27] | IGRA, TST, CXR | No | Yes | Yes | Yes | No | No |
Proportion of studies reporting outcome | 1/11 | 11/11 | 7/11 | 7/11 | 4/11 | 1/11 | |
Studies evaluating latent TB infection screening in people living with HIV | |||||||
Ní Cheallaigh et al. [28] | IGRA, TST | No | Yes | Yes | No | No | No |
Ali et al. [29] | TST, CXR | No | Yes | No | No | No | No |
Proportion of studies reporting outcome | 0/2 | 2/2 | 1/2 | 0/2 | 0/2 | 0/2 | |
Studies evaluating latent TB infection screening in recent TB contacts or prior to BCG vaccination | |||||||
Higgins et al. [30] | TST | Yes | Yes | No | Yes | No | No |
Glynn et al. [31] | Unclear | Yes | Yes | No | Yes | Yes | No |
O’Donovan et al. [32] | Unclear | No | Yes | No | No | No | No |
O’Meara et al. [33] | TST, CXR | Yes | Yes | No | No | No | No |
O’Sullivan et al. [34] | TST, CXR | No | Yes | No | No | No | No |
Bambury et al. [35] | Unclear | Yes | Yes | No | No | No | No |
Gaensbaeur et al. [36] | TST, CXR | Yes | Yes | No | No | No | No |
Hennessy [37] | TST, CXR | No | Yes | No | No | No | No |
Tam et al. [38] | TST, CXR | No | No | Yes | No | Yes | No |
Proportion of studies reporting outcome | 5/9 | 8/9 | 1/9 | 2/9 | 2/9 | 0/9 | |
Studies evaluating latent TB infection screening in asylum seekers | |||||||
Millar et al. [39] | Unclear | No | Yes | No | No | No | No |
Doyle et al. [40] | TST, CXR | No | Yes | No | Yes | No | No |
Proportion of studies reporting outcome | 0/2 | 2/2 | 0/2 | ½ | 0/2 | 0/2 | |
Studies evaluating latent TB infection screening in health care workers | |||||||
Ali et al. [29] | TST, CXR | No | Yes | No | No | No | No |
Smyth et al. [41] | TST | No | Yes | No | No | No | No |
Kelly et al. [42] | IGRA, TST | No | Yes | Yes | Yes | Yes | No |
Power et al. [43] | TST, CXR | No | Yes | No | No | No | No |
Arya et al. [44] | TST, CXR | No | No | No | Yes | Yes | No |
Proportion of studies reporting outcome | 0/5 | 4/5 | 1/5 | 2/5 | 2/5 | 0/5 | |
Proportion of all studies reporting outcome | 6/28 | 26/28 | 10/28 | 12/28 | 8/28 | 1/28 |
Risk of bias assessment
Study | Total risk of bias score | Risk of bias |
---|---|---|
Studies evaluating latent TB infection screening in patients undergoing immunosuppression | ||
Gnanasekaran et al. [17] | 7 | Low |
O’Flynn et al. [18] | 0 | High |
Awan et al. [19] | 0 | High |
O’Flynn et al. [20] | 2 | High |
Hurley et al. [21] | 1 | High |
Safwat et al. [22] | 1 | High |
Haroon et al. [23] | 4 | Moderate |
O’Flynn [45] | 4 | Moderate |
Martin et al. [25] | 4 | Moderate |
Jordan et al. [26] | 0 | High |
Kelly et al. [27] | 4 | Moderate |
Studies evaluating latent TB infection screening in people living with HIV | ||
Ni Cheallaigh et al. [28] | 3 | Moderate |
Ali et al. [29] | 2 | High |
Studies evaluating latent TB infection screening in recent TB contacts or prior to BCG vaccination | ||
Higgins et al. [30] | 2 | High |
Glynn et al. [31] | 0 | High |
O’Donovan et al. [32] | 0 | High |
O’Meara et al. [33] | 6 | Low |
O’Sullivan et al. [34] | 0 | High |
Bambury et al. [35] | 0 | High |
Gaensbaeur et al. [36] | 4 | Moderate |
Hennessy [37] | 1 | High |
Tam et al. [38] | N/a | N/a |
Studies evaluating latent TB infection screening in vulnerable population groups | ||
Millar et al. [39] | 0 | High |
Doyle et al. [40] | 5 | Moderate |
Studies evaluating latent TB infection screening in health care workers | ||
Ali et al. [29] | 2 | High |
Smyth et al. [41] | 1 | High |
Kelly et al. [42] | 2 | High |
Power et al. [43] | 0 | High |
Arya et al. [44] | N/a | N/a |
Latent TB infection screening and treatment outcomes in patients undergoing immunosuppression
Study | Risk of bias score | Target sample size/proportion of target sample screened | Proportion with a positive screening test | Proportion offered prophylaxis | Proportion accepting prophylaxis | Proportion completing prophylaxis | Cost of screening/ treatment |
---|---|---|---|---|---|---|---|
Risk of bias moderate-low | |||||||
Gnanasekar-an et al. [17] | 7 | 37/39 (95%) | IGRA + 2/37 (5%) | 2/2 | 2/2 | 2/2 | NR |
Haroon et al. [23] | 4 | 132 | TST + 23/132 (17%) | 23/23 | 23/23 | 14/23 (61%) | NR |
O’Flynn [46]* | 4 | 188 | TST + 22/165 (13%) | 33/33 | 33/33 | NR | NR |
IGRA + 11/161 (7%) | |||||||
Martin et al. [25] | 4 | 150 | TST + 27/150 (18%) | NR | NR | NR | NR |
IGRA (T-SPOT) + 14/143 (10%) | |||||||
IGRA (QFT) + 5/70 (7%) | |||||||
Kelly et al. [27] | 4 | 101 | IGRA + 5/71 (7%) | 5/5 | 5/5 | NR | NR |
Risk of bias high | |||||||
O’Flynn et al. [18] | 0 | 70 | Unknown test 11/70 (16%) | NR | NR | NR | NR |
Awan et al. [19] | 0 | 25 | TST + 3/25(12%) | 3/3 | 3/3 | 3/3 | NR |
IGRA + 2/25(8%) | |||||||
O’Flynn et al. [20] | 2 | 109 | IGRA + 9/109 (8%) | 9/9 | 9/9 | NR | NR |
Hurley et al. [21] | 1 | 101 | TST + 9/101 (9%) | NR | NR | NR | NR |
IGRA + 8/101 (8%) | |||||||
Safwat et al. [22] | 1 | 78 | TST + 17/41 (41%) | NR | NR | NR | NR |
IGRA + 12/78 (15%) | |||||||
Jordan et al. [26] | 0 | 63 | TST + 21/63 (33%) | 22/22 | 22/22 | 22/22 | Cost of LTBI management 4 IGRA + = €1,652 18 TST + = €6,174 |
IGRA + 4/63 (6%) |
Latent TB infection screening and treatment outcomes in people living with HIV
Latent TB infection screening and treatment outcomes in recent TB contacts or prior to BCG vaccination
Study | Risk of bias score | Target sample size/proportion of target sample screened | Proportion screened positive | Proportion offered prophylaxis | Proportion accepting prophylaxis | Proportion completing prophylaxis | Cost of screening/treatment |
---|---|---|---|---|---|---|---|
Risk of bias moderate-low | |||||||
O’Meara et al. [33] | 6 | 244/307 (79%) | TST 17/191 (9%) | NR | NR | NR | NR |
Gaensbaeur et al. [36] | 4 | 268 | TST 20/268 (7%) | NR | NR | NR | NR |
Risk of bias high | |||||||
Higgins et al. [30] | 2 | 260/268 (97%) | TST 48/260 (19%) | NR | 15/48 (31%) | NR | NR |
Glynn et al. [31] | 0 | 585/701 (83%) | Unknown test 76/585 (13%) | 46/76 (71%) | NR | 15/46 (33%) | NR |
O’Donovan et al. [32] | 0 | 71 | Unknown test 26/71 (37%) | NR | NR | NR | NR |
O’Sullivan et al. [34] | 0 | 1200 | TST > 60/1200 (> 5%) | NR | NR | NR | NR |
Bambury et al. [35] | 0 | 1082 | Unknown 223/1082 (21%) | NR | 150/223 (67%) | 116/150 (77%) | NR |
Hennessy [37] | 1 | NR | TST 13/1854 (< 1%) | NR | NR | NR | NR |
Tam et al. [38] | N/a | NR | NR | 13/13 (100%) | NR | 10/13 (77%) | NR |
Latent TB infection screening and treatment outcomes in asylum seekers
Latent TB infection screening and treatment outcomes in health care workers
Study | Risk of bias score | Target sample size/proportion of target sample screened | Proportion screened positive | Proportion offered prophylaxis | Proportion accepting prophylaxis | Proportion completing prophylaxis | Cost of screening/treatment |
---|---|---|---|---|---|---|---|
Ali et al. [29] | 2 | 2410 | TST 765/2410 (32%) | NR | NR | NR | NR |
Smyth et al. [41] | 1 | 41 | TST 23/42 (56%) | NR | NR | NR | NR |
Kelly et al. [42]a | 2 | 505 | TST/IGRA 87/505 (17%) | 74/87 (85%) | 19/74 (26%) | 19/19 (100%) | NR |
Power et al. [43]b | 0 | 54 | TST 3/54 (6%) | NR | NR | NR | NR |
Arya et al. [44] | N/a | 243 | 243 | NR | 50/85 (59%) | 31/50 (62%) | NR |
Discussion
Conclusion
Appendix 1. PRISMA checklist
Section/topic | No | Checklist item | Reported on page no |
---|---|---|---|
TITLE
| |||
Title | 1 | Identify the report as a systematic review, meta-analysis, or both | 1 |
ABSTRACT
| |||
Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number | 2 |
Introduction
| |||
Rationale | 3 | Describe the rationale for the review in the context of what is already known | 3–4 |
Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS) | 4 |
Methods
| |||
Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number | 5 |
Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale | 5 |
Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched | 5 |
Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated | Appendix 2 |
Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | Page 5 and Appendix 2 |
Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators | Page 5 and Appendix 2 |
Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made | 5 |
Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis | Page 5, Appendix 2 and 3 |
Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means) | 5 |
Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency | 5 |
Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies) | Appendix 3 |
Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified | No additional analyses |
Results
| |||
Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram | Figure 1 |
Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations | Page 6 and Table 3 |
Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12) | Page 8 and Table 4 |
Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot | Pages 10–14 |
Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency | Pages 10–14 |
Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15) | Appendix 3 |
Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]) | No additional analyses |
Discussion
| |||
Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers) | Pages 14–15 |
Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias) | Pages 14–15 |
Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research | Page 15 |
Funding
| |||
Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review | Page 16 |
Appendix 2. Protocol for a systematic review of studies evaluating latent TB screening in the Republic of Ireland
Introduction
All age groups | All those aged ≤ 35 years of age or ≤ 55 years of age if supervised directly observed therapy is available | ||
---|---|---|---|
1 | Recent converters | 5 | Persons from countries with high TB endemicity |
2 | HIV-positive individuals | 6 | People who are homeless |
3 | Persons receiving immunosuppressive therapy | 7 | People who use intravenous drugs |
4 | Persons with evidence of old healed TB lesions on chest X-ray | 8 | Health care workers |
Aim
Objectives
Methods
Included studies
Outcomes
Search methods
Search strategy
1 | ‘tuberculosis’/exp OR ‘tuberculosis’ |
---|---|
2 | ‘mycobacterium tuberculosis’/exp OR ‘mycobacterium tuberculosis’ |
3 | ‘latent tuberculosis’/exp OR ‘latent tuberculosis’ |
4 | #1 OR #2 OR #3 |
5 | ‘ireland’/exp OR ‘ireland’ |
6 | ‘screening’/exp OR ‘screening’ |
7 | ‘microorganism detection’/exp OR ‘microorganism detection’ |
8 | ‘assessment of humans’/exp OR ‘assessment of humans’ |
9 | #6 OR #7 OR #8 |
10 | (‘interferon’/exp OR interferon) AND gamma AND (‘release’/exp OR release) AND (‘assay’/exp OR assay) |
11 | ‘tuberculin test’/exp OR ‘tuberculin test’ |
12 | #10 OR #11 |
13 | #4 AND #5 AND #9 AND #12 |
MEDLINE (OVID) search strategy
Web of Science search strategy
Google Scholar search strategy
Conference Abstract Search Strategy
Publication |
---|
Royal College of Physicians of Ireland Faculty of Public Health Summer and Winter Scientific Meetings |
1.Irish Journal of Medical Science, December 2016, Issue 12 Supplement, Pages 527–561 Proceedings of the Faculty of Public Health Medicine, Summer & Winter Scientific Meetings 2015 2. Irish Journal of Medical Science, August 2012, Issue 5 Supplement, Pages 121–127 Faculty of Public Health Medicine, Royal College of Physicians of Ireland—Summer Scientific Meeting, 23rd—24th May, 2012, Dublin 3. Irish Journal of Medical Science, August 2012, Issue 4 Supplement, Pages 109–119 Faculty of Public Health Medicine, Royal College of Physicians of Ireland—Winter Scientific Meeting Abstracts 14th December, 2011, Dublin 4. Irish Journal of Medical Science July 2011, Issue 7 Supplement, Pages 221–232 Faculty of Public health Medicine Summer Scientific meeting, 25th & 26th May 2011, RCPI, Dublin 5. Irish Journal of Medical Science June 2011, Issue 6 Supplement, Pages 213–220 Faculty of Public Health Medicine, Winter Scientific Meeting, RCPI Dublin, 8th Dec 2010 6. Irish Journal of Medical Science October 2010, Issue 11 Supplement, Pages 413–446 The Summer 2008, Winter 2008, Summer 2009 & Winter 2009 Scientific Meetings of the Faculty of Public Health Medicine of the Royal College of Physicians of Ireland 7. Irish Journal of Medical Science August 2010, Issue 8 Supplement, Pages 303–311 Summer Scientific Meeting of the Faculty of Public Health Medicine of the Royal College of Physicians of Ireland, Dublin, 24 & 25th May 2010 8. Irish Journal of Medical Science, Volume 169, Issue 4 Supplement, April 2000, Faculty of Public Health Medicine Summer Scientific Meeting 1999 |
Health Service Executive |
Irish Journal of Medical Science, October 2016, Issue 8 Supplement, Pages 421–437 2nd Annual Multidisciplinary Galway University Hospitals Research Symposium, 2016 |
Infectious Diseases Society of Ireland |
Annual Scientific Meetings Abstracts 2011- 2019, www.idsociety.ie |
Irish Nephrology Society |
Annual Scientific Meeting 2018, https://nephrology.ie/ins-annual-meeting/ |
Royal Academy of Medicine in Ireland |
1. Irish Journal Medical Science 188, 31–127 (2019). https://doi.org/10.1007/s11845-019-02053-0 Proceedings of the Intern Section of the Royal Academy of Medicine in Ireland (RAMI) Venue: Mater, Dublin 7 on Saturday 2nd February 2019 2. Irish Journal of Medical Science, March 2018, Issue 3 Supplement, Pages 17–113 Proceedings of the RAMI Intern Section Meeting, Saturday 27 January 2018 3. Irish Journal of Medical Science, June 2017, Issue 6 Supplement, Pages 171–280 Proceedings of the RAMI Intern Section Meeting, 14 January 2017 4. Irish Journal of Medical Science, June 2016, Issue 5 Supplement, Pages 187–299 Proceedings of the RAMI Section of Interns Study Day Saturday 30th January 2016 5. Irish Journal of Medical Science, July 2015, Volume 184, Supplement 7, pp 249–344 | RAMI Intern Section Meeting held on 31st January 2015 6. Irish Journal of Medical Science, July 2014, Issue 4 Supplement, Pages 119–199 Proceedings of the RAMI Intern Section Meeting, 18th January 2014 7. Irish Journal of Medical Science June 2013, Issue 5 Supplement, Pages 143–178 Proceedings of the RAMI Section of Interns Study Day, 26th January 2013, Royal College of Physicians of Ireland 8. Irish Journal of Medical Science July 2012, Issue 3 Supplement, Pages 83–107 Proceedings of the RAMI Section of Interns Study Day, 21st April 2012 9. Irish Journal of Medical Science Volume 170, Issue 3 Supplement, October–December 2001, Royal Academy of Medicine in Ireland Jacqueline Horgan Epidemiology Prize November 2001 10. Irish Journal of Medical Science, Volume 169, Issue 4 Supplement, April 2000, Royal Academy of Medicine in Ireland Jacqueline Horgan Epidemiology Prize 1999 |
Irish Society of Gastroenterology |
1. Irish Journal of Medical Science February 2015, Issue 3 Supplement, Pages 67–102 Irish Society of Gastroenterology, Summer Meeting, 12th and 13th June 2014 2. Irish Journal of Medical Science, Volume 184, Issue 6 Supplement, June 2015, Irish Society of Gastroenterology – Winter Meeting 2014 3. Irish Journal of Medical Science, February 2015, Issue 2 Supplement, Pages 19–65 Irish Society of Gastroentrology, Winter Meeting, 22nd and 23rd November 2013 |
Irish Society of Rheumatology |
1. Irish Journal of Medical Science, April 2014, Issue 3 Supplement, Pages 87–118 Irish Society for Rheumatology, Autumn Meeting 2013, 19th & 20th September 2013 2. Irish Journal of Medical Science, June 2012, Issue 2 Supplement, Pages 49–81 Irish Society for Rheumatology, Autumn Meeting 2011, 29th & 30th September 2011 3. Irish Journal of Medical Science, June 2011, Issue 5 Supplement, Articles 169–169 Irish Society of Rheumatology Autumn Scientific Meeting 2010 4. Irish Journal of Medical Science, November 2010, Issue 14 Supplement, Pages 539–574 Irish Society for Rheumatology & Irish Rheumatology Health Professionals Society – Autumn Scientific Meeting 2009 5. Irish Journal of Medical Science March 2008, Issue 3 Supplement, Pages 71–108 Irish Society for Rheumatology (ISR) and Irish Rheumatology Health Professionals Society (IRHPS) combined AGM 2007 6. Irish Journal of Medical Science, Volume 169, Issue 4 Supplement, April 2000, Irish Society for Rheumatology Meeting October 1999 |
Irish Thoracic Society |
1. Irish Journal of Medical Science 188, 255–320 (2019). Irish Thoracic Society Annual Scientific Meeting 2019 2. Irish Journal of Medical Science, August 2018, Issue 8 Supplement, Pages 237–303 Irish Thoracic Society Annual Scientific Meeting, 23rd–24th November 2018 3. Irish Journal of Medical Science, October 2017, Issue 10 Supplement, Pages 387–445 Irish Thoracic Society Annual Scientific Meeting 2017, 10th–11th November 2017 4. Irish Journal of Medical Science, November 2016, Issue 9 Supplement, Pages 439–508, ITS Annual Scientific Meeting 2016 5. Irish Journal of Medical Science, Irish Thoracic Society Annual Scientific Meeting 2017, 10th–11th November 2017 6. Irish Thoracic Society Annual Scientific Meeting 2015, 13th–14th November 2015, Issue 11 Supplement, Pages 475–547 7. Irish Journal of Medical Science, Volume 183, Issue 11 Supplement, November 2014, Irish Thoracic Society Annual Scientific Meeting 2014 8. Irish Journal of Medical Science, November 2013, Issue 10 Supplement, Pages 427–486 Irish Thoracic Society Annual Scientific Meeting 2013, 15th – 16th November 9. Irish Journal of Medical Science, November 2012, Issue 10 Supplement, Pages 369–437 Irish Thoracic Society Annual Scientific Meeting 2012, 23rd – 24th November, Limerick, Ireland 10. Irish Journal of Medical Science, November 2011, Issue 12 Supplement, Articles 411–411 Irish Thoracic Society Annual Scientific Meeting 2011, 11th -12th November, 11. Irish Journal of Medical Science, November 2009, Issue 11 Supplement, Articles 423–423 Irish Thoracic Society Annual Scientific Meeting 2009 12. Irish Journal of Medical Science, November 2008, Issue 13 Supplement, Pages 425–482 Irish Thoracic Society Annual Scientific Meeting, 2008 13. Irish Journal of Medical Science, November 2007, Issue 10 Supplement, Pages 385–426 Irish Thoracic Society Annual Scientific Meeting 2007 14. Irish Journal of Medical Science, Volume 170, Issue 3 Supplement, October–December 2001 Irish Thoracic Society Annual Scientific Meeting 2000 15. Irish Journal of Medical Science Volume 169, Issue 4 Supplement, April 2000, Irish Thoracic Society Annual Scientific Meeting 1999 16. Irish Journal of Medical Science April 2000, 169:24 Irish Thoracic Society Annual Scientific Meeting 13th & 14th November 1998 |
Datapoint collected | Description |
---|---|
Screening test used | Test used to determine if further assessment was necessary to confirm or deny a diagnosis of latent TB Included IGRA, TST, CXR |
Indication for screening | The reason why LTBI screening was performed |
The proportion of people screened out of target sample population | The proportion of people screened out of the total group of people targeted as defined by the authors |
The proportion of patients screened with a positive test | The proportion of all patients screened who have a positive chest X-ray, TST, or IGRA |
The proportion of patients with a positive test offered LTBI treatment | |
The proportion of patients offered LTBI treatment who accepted treatment | |
The proportion of patients on treatment for LTBI who completed treatment | |
The cost of screening for LTBI and or treatment |
Risk of bias assessment
Data extraction
Appendix 3. Risk of bias assessment tool
Domain and Score | Criteria |
---|---|
Quality of sampling method | |
0 | A convenience sample of the target population was used |
1 | A random sample of the target population was used |
2 | A national survey or multisite random sample of the target population was used |
Quality of selection method | |
0 | There were no exclusion criteria stated or a risk factor for LTBI was an exclusion criterion |
1 | Exclusion criteria were stated and a risk factor for LTBI was not an exclusion criteria |
2 | The means of identification of TB was stated |
Response rate | |
0 | Not reported |
1 | The proportion of the sample screened is reported and is under 65% |
2 | The proportion of the sample screened is reported and is 65% or above |
Quality of prevalence assessment | |
0 | TST cut-off at 10 mm was not present/Indeterminate IGRA results were not stated |
1 | TST cut-off at 10 mm was present/ Indeterminate IGRA results were stated |
2 | TST cut-off at 5 or 15 mm was present as well/ Indeterminate IGRA results constituted < 10% |
Study | Quality of sampling method | Quality of selection method | Response rate | Quality of prevalence assessment | Total risk of bias score | Risk of bias |
---|---|---|---|---|---|---|
Studies evaluating latent TB infection screening in patients undergoing immunosuppression | ||||||
Gnanasekaran et al. [357] | 1 | 2 | 2 | 2 | 7 | Low |
O’Flynn et al. [358] | 0 | 0 | 0 | 0 | 0 | High |
Awan et al. [359] | 0 | 0 | 0 | 0 | 0 | High |
O’Flynn et al. [360] | 0 | 2 | 0 | 0 | 2 | High |
Hurley et al. [361] | 0 | 0 | 0 | 1 | 1 | High |
Safwat et al. [362] | 0 | 0 | 0 | 1 | 1 | High |
Haroon et al. 2012 [363] | 0 | 2 | 2 | 0 | 4 | Moderate |
O’Flynn [402] | 0 | 2 | 0 | 2 | 4 | Moderate |
Martin et al. [365] | 0 | 2 | 0 | 2 | 4 | Moderate |
Jordan et al. [366] | 0 | 0 | 0 | 0 | 0 | High |
Kelly et al. [367] | 0 | 2 | 2 | 0 | 4 | Moderate |
Studies evaluating latent TB infection screening in people living with HIV | ||||||
Ni Cheallaigh et al. [368] | 0 | 1 | 0 | 2 | 3 | Moderate |
Ali et al. [369] | 0 | 2 | 0 | 0 | 2 | High |
Studies evaluating latent TB infection screening in recent TB contacts or prior to BCG vaccination | ||||||
Higgins et al. [370] | 0 | 0 | 2 | 0 | 2 | High |
Glynn et al. [371] | 0 | 0 | 0 | 0 | 0 | High |
O’Donovan et al. [372] | 0 | 0 | 0 | 0 | 0 | High |
O’Meara et al. 2005 [373] | 0 | 2 | 2 | 2 | 6 | Low |
O’Sullivan et al. 2000 [374] | 0 | 1 | 0 | 0 | 0 | High |
Bambury et al. [375] | 0 | 0 | 0 | 0 | 0 | High |
Gaensbaeur et al. [376] | 0 | 2 | 2 | 0 | 4 | Moderate |
Hennessy [377] | 0 | 1 | 0 | 0 | 1 | High |
Tam et al. [378] | N/a | N/a | N/a | N/a | N/a | N/a |
Studies evaluating latent TB infection screening in vulnerable population groups | ||||||
Millar et al. [379] | 0 | 0 | 0 | 0 | 0 | High |
Doyle et al. [380] | 0 | 2 | 2 | 1 | 5 | Moderate |
Studies evaluating latent TB infection screening in healthcare workers | ||||||
Ali et al. [369] | 0 | 2 | 0 | 0 | 2 | High |
Smyth et al. [403] | 0 | 0 | 0 | 1 | 1 | High |
Kelly et al. [381] | 0 | 2 | 0 | 0 | 2 | High |
Power et al. [382] | 0 | 0 | 0 | 0 | 0 | High |
Arya et al. [404] | N/a | N/a | N/a | N/a | N/a | N/a |